A
0.768
-0.02 (-2.12%)
| 前收盘价格 | 0.784 |
| 收盘价格 | 0.772 |
| 成交量 | 270,420 |
| 平均成交量 (3个月) | 424,032 |
| 市值 | 73,873,472 |
| 预期市盈率 (P/E Forward) | 14.27 |
| 价格/销量 (P/S) | 0.500 |
| 股市价格/股市净资产 (P/B) | 0.650 |
| 52周波幅 | |
| 利润日期 | 10 Nov 2025 |
| 营业毛利率 | -25.72% |
| 营业利益率 (TTM) | -48.87% |
| 稀释每股收益 (EPS TTM) | -0.320 |
| 季度收入增长率 (YOY) | -18.40% |
| 总债务/股东权益 (D/E MRQ) | 37.12% |
| 流动比率 (MRQ) | 1.66 |
| 营业现金流 (OCF TTM) | 6.36 M |
| 杠杆自由现金流 (LFCF TTM) | 16.48 M |
| 资产报酬率 (ROA TTM) | -6.60% |
| 股东权益报酬率 (ROE TTM) | -25.19% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 看涨 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 看涨 | 混合的 | |
| 股票 | Assertio Holdings, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
-0.8
| 分析师共识 | -2.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | 2.0 |
| 平均 | -0.75 |
|
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Value |
| 内部持股比例 | 2.52% |
| 机构持股比例 | 26.92% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合